Clinical and Preclinical Systematic Review of Astragalus Membranaceus for Viral Myocarditis
Joint Authors
Zheng, Qun
Zhuang, Zhuang
Wang, Zi-Hao
Deng, Li-Hui
Jin, Wang-Jun
Huang, Zi-Jun
Wang, Yan
Zheng, Guo-qing
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-23, 23 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-11-02
Country of Publication
Egypt
No. of Pages
23
Main Subjects
Abstract EN
Astragalus membranaceus (AM) is a traditional Chinese medicine, which possesses a variety of biological activities in the cardiovascular systems.
We conducted a clinical and preclinical systematic review of 28 randomized clinical control studies with 2522 participants and 16 animal studies with 634 animals to evaluate the efficacy, safety, and possible mechanisms of AM for viral myocarditis (VM).
The search strategies were performed in 7 databases from inception to January 2020.
Application of the Cochrane Collaboration’s tool 7-item checklist, SYRCLE’s tool 10-item checklist, and Rev-Man 5.3 software to analyze the risk of bias of studies and data.
The results show the score of clinical study quality ranged from 3 to 7 points with an average of 3.32, and the score of animal study quality ranged from 2 to 5 points with an average of 3.
In clinical study, AM significantly reduced serum myocardial enzymes and cardiac troponin I levels and improved the clinical treatment efficiency in VM patients compared with the control group (P<0.05).
There was no significant difference in the incidence of adverse reactions (P>0.05).
Significant increase of the survival rate and decrease of the cardiac cardiology score, cardiac enzymes, and cardiac troponin I were compared with the placebo group in animal studies (P<0.05).
The possible mechanisms of AM are largely through antivirus and antivirus receptors, anti-inflammatory, antioxidation, antiapoptotic, antifibrosis, and reducing cardiac calcium load.
In conclusion, the findings suggested that AM is a cardioprotection candidate drug for VM.
American Psychological Association (APA)
Zheng, Qun& Zhuang, Zhuang& Wang, Zi-Hao& Deng, Li-Hui& Jin, Wang-Jun& Huang, Zi-Jun…[et al.]. 2020. Clinical and Preclinical Systematic Review of Astragalus Membranaceus for Viral Myocarditis. Oxidative Medicine and Cellular Longevity،Vol. 2020, no. 2020, pp.1-23.
https://search.emarefa.net/detail/BIM-1203756
Modern Language Association (MLA)
Zheng, Qun…[et al.]. Clinical and Preclinical Systematic Review of Astragalus Membranaceus for Viral Myocarditis. Oxidative Medicine and Cellular Longevity No. 2020 (2020), pp.1-23.
https://search.emarefa.net/detail/BIM-1203756
American Medical Association (AMA)
Zheng, Qun& Zhuang, Zhuang& Wang, Zi-Hao& Deng, Li-Hui& Jin, Wang-Jun& Huang, Zi-Jun…[et al.]. Clinical and Preclinical Systematic Review of Astragalus Membranaceus for Viral Myocarditis. Oxidative Medicine and Cellular Longevity. 2020. Vol. 2020, no. 2020, pp.1-23.
https://search.emarefa.net/detail/BIM-1203756
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1203756